Oncology, AI, genomics, proteomics, radiomics, ML, diagnostics

Digitalis Ventures

Accomplice

KdT Ventures

BlueCross BlueShield Venture Partners

T. Chen Fong

Frederic Kerrest

Jonathan J. Fleming

Stanley M. Marks

The Blue Venture Fund

Action Potential Venture Capital

Life Extension Ventures

MassMutual

Onc.AI

We're absolutely thrilled to announce Kevin Masukawa Ph.D. has been appointed Chief Commercial Officer at Onc.AI -- where he'll lead Sales, Marketing and Market-Access organizations. Kevin brings significant oncology sales and strategic marketing experience with past tenures at L.E.K, Genentech (12+ years) and most recently as VP Oncology Marketing at Natera where he architected and executed the market adoption strategy for the breakthrough Signatera test for Molecular Residual Disease (MRD) in solid tumors.  Kevin holds a PhD in Chemical Biology from UCSF and BSc in Biochemistry from UCSD.

If you are at ASCO today, join us now for our last poster session presented by Dr. George Simon, and following discussion at 4:30pm to learn more about care delivery and regulatory policy.

📚 Abstract Title: "AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC."
🗓️ Poster Session Display Date and Time:
6/5/2023, 1:15 PM-4:15 PM
📍 Poster Board Number: 111

🗣️ Poster Discussion Session Date and Time:
6/5/2023, 4:30 PM-6:00 PM
🎙️ Session Type/Title: Poster Discussion Session - Care Delivery and Regulatory Policy

Don't miss this exciting opportunity to explore the innovative research on AI-based radiomic biomarkers and their potential to predict PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC patients across different PD-L1 expression categories!

#ASCO2023 #NSCLC #AIinMedicine #Immunotherapy 

Good morning ☀  If you are in Chicago at #ASCO2023, we invite you to attend an exciting poster session this morning: join us to explore the remarkable findings presented by Dr. Chiharu Sako in the field of non-small cell metastatic lung cancer.

Poster Details:
🔍 Temporary Abstract Submission ID: 418076
📑 Abstract Number for Publication: 9124
📚 Abstract Title: "Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy."
🗓️ Session Date and Time:
6/4/2023, 8:00 AM-11:00 AM

Don't miss this opportunity to delve into the latest advancements in the management of advanced NSCLC and engage in meaningful discussions, exchange knowledge, and connect with fellow professionals in the field.

#ASCO2023 #LungCancerResearch #NSCLC  #MedicalAdvancements

Join us at #ASCO2023 to learn about our AI-powered clinical management products. Don't miss our abstract presentations: 

📌 Abstract #9124, Poster #112 (Chiharu Sako, PhD -- Onc.AI) 
📌 Abstract #1517, Poster #111 (George R. Simon, MD, FACP, FCCP -- Moffitt Cancer Center)

Additionally, we're hosting an exclusive gathering on Sunday at 6:30pm for our friends, clinical advisors and partners with limited spots available. 

Calling medical oncologists interested in AI and immunotherapy-focused clinical management solutions. Reach out to contact@onc.ai with "High Spirits" in the subject line and we'll follow-up to get you in! 

Experience the future of oncology with us at #ASCO2023!

#OncologyInnovation #AIinMedicine #ClinicalManagement #Immunotherapy

Digital Ocean

Co-Founder at Onc.AI

Akshay Nanduri

CEO, Founder

Business Management

Petr Jordan

VP Software, Founder

Salmaan Ahmed

VP Data Partnerships & Operations

Lester Boeh

VP of AL/ML & Chief Software Architect

Rita Ciaravino

VP of Business Development and Founding Team Member

Zeenat Patrawala

Head of People Ops

Nadya Pierre, SHRM-SCP

Project Manager

Milana Tatarintseva

Operations

Ross McCall - MS, MBA

Thomas Hawes

Julie Hambleton

Emir Sandhu

David Diaz-Casariego

Co-Founder and CEO

VP Software and Founder

Western US Companies With Fewer Than 100 Employees (Top 10K)

San Francisco Bay Area Companies With More Than 10 Employees (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than $1M in Revenue (Top 10K)

Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment.

It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

National Cancer Institute

Grant - Onc.AI

Series A - Onc.AI

Seed Round - Onc.AI

San Carlos

California

United States

North America

Onc.AI Serial Imaging Response Score Outperforms Traditional Methods for Early Assessment of NSCLC Immunotherapy Outcomes

Onc.AI to Present Collaboration Results Demonstrating Immunotherapy Response Prediction Using a Radiomic Signature in Late-Stage Lung Cancer

MassMutual backs Onc.AI

Onc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture Capital

AI models developed by Onc.AI utilize diagnostic imaging, EMR, labs, genomics data to support oncology decision making.

A product designed to assist medical oncologists in making treatment decisions for metastatic lung cancer patients treated with PD-1 immunotherapy.

Philippines

Asia

Bangladesh

Mexico

ONC.AI is a healthcare technology company specializing in the development of AI-driven solutions for oncology and cancer care.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	0439635a
crunchbase profile	general	Nov 22, 2024 9:04 AM	8a3631e1
li profile	general	Feb 6, 2024 9:06 AM	1d0ad138
translate crunchbase fundingrounds	general	Nov 22, 2024 1:54 PM	5d549253
peers	general	Feb 6, 2024 9:06 AM	d6047a6b
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

AI:ONC

ONC.AI